The OHE report on incentives to tackle Anti-Microbial Resistance. (May 5th 2017)
The Office of Health Economic (UK) has released a report that assess the relevance
READ MOREThe Office of Health Economic (UK) has released a report that assess the relevance
READ MOREMutabilis will be represented at the European Congress on Clinical Microbiology and Infectious Diseases (ECCMID) in Vienne from April 22nd to 25th 2017.
READ MOREMutabilis will be represented at the “Superdrugs for Superbugs” conference in London on March 20th and 21st 2017.
READ MOREThe Organization has published its first list of the 12 most worrying pathogens
READ MOREMutabilis will be at the Gordon Research Conferences in Italy.
READ MOREConference on Retrovirus and Opportunistic Infections.
READ MOREThe UK Review on Anti-Microbial Resistance headed by Jim O’Neil
READ MOREThe Beam Alliance is an association of about 50 European SMEs involved in the development of antibiotics, antimicrobials and alternative approaches. Its objective is to give a voice to the SMEs, pivotal actors of the value chain of Antibiotics R&D. Drive-AB is a IMI project part of the New Drugs For Bad Bugs (ND4BB) umbrella whose objectives is to suggest new economic models tailored to rejuvenate the antibiotics R&D pipeline. It ambitioned to gather all relevant stakeholders but the SMEs had been overlooked. With the addition of BEAM all the […]
READ MORE